Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Amortization of Deferred Charges (2018 - 2025)

Collegium Pharmaceutical (COLL) has 7 years of Amortization of Deferred Charges data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges fell 10.39% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $5.3 million, down 11.22%, while the annual FY2025 figure was $5.3 million, 11.22% down from the prior year.
  • Amortization of Deferred Charges reached $1.3 million in Q4 2025 per COLL's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $2.5 million in Q2 2022 and bottomed at $779000.0 in Q4 2021.
  • Average Amortization of Deferred Charges over 5 years is $1.6 million, with a median of $1.4 million recorded in 2024.
  • Peak YoY movement for Amortization of Deferred Charges: plummeted 69.39% in 2021, then skyrocketed 205.91% in 2022.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $779000.0 in 2021, then surged by 205.91% to $2.4 million in 2022, then dropped by 17.62% to $2.0 million in 2023, then decreased by 27.46% to $1.4 million in 2024, then decreased by 10.39% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $1.3 million in Q4 2025, $1.3 million in Q3 2025, and $1.4 million in Q2 2025.